Today: 21 May 2026
Target stock jumps on activist stake report as investors eye next steps
29 December 2025
2 mins read

Target stock jumps on activist stake report as investors eye next steps

NEW YORK, December 29, 2025, 00:41 ET — Market closed

  • Target shares last closed up 3.1% at $99.55 after a report that activist investor Toms Capital Investment Management built a stake.
  • The size of the position and any demands were not disclosed.
  • Traders are watching for filings or public moves from the activist ahead of the week’s year-end data and thin trading.

Target Corp shares last closed up 3.1% at $99.55, after the Financial Times reported activist investor Toms Capital Investment Management had taken a significant stake in the retailer.

The report matters now because Target is trying to restart growth after a prolonged slump, and activist investors typically buy stakes and push for strategy or governance changes to lift returns.

It also lands as Target prepares for a leadership change that has already raised investor questions, setting up a volatile mix of scrutiny and potential shakeups.

The Financial Times report did not disclose the size of TCIM’s stake or what it may ask for, Reuters reported. TCIM did not respond to Reuters’ requests for comment.

Target said it “maintain[s] a regular dialogue with the investment community,” adding that its top priority is “getting back to growth,” according to a statement to Reuters. Reuters

Target’s stock has lost more than 28% this year, after the company posted three straight quarters of falling comparable sales, a key retail gauge that tracks sales at stores open at least a year.

In August, Target tapped company veteran Michael Fiddelke to revive growth. He is set to take over as CEO in February while continuing to report to current CEO Brian Cornell, who is due to become executive chairman, Reuters reported.

That governance structure has drawn criticism, and the shareholder group The Accountability Board has pushed a proposal urging Target to appoint an independent chairman, Reuters reported.

TCIM has recently pushed for changes at other companies including Kellanova and U.S. Steel, and it took a stake in Kenvue ahead of its sale to Kimberly-Clark last month for about $40 billion, Reuters said.

Target laid out plans to spend an additional $1 billion in 2026 on new store openings and remodels, and it has cut 1,800 corporate roles as part of a broader restructuring, Reuters reported.

Target is no stranger to activists. In 2009, it fought a proxy battle — a contest for shareholder votes — with Pershing Square’s Bill Ackman, whose real-estate spin-off plan was rejected by shareholders, Reuters reported.

Real estate may again be a pressure point. Target owns about 75% of its real estate, including land, according to analysis by UBS analyst Michael Lasser cited by Reuters.

Neil Saunders, managing director at retail research firm GlobalData, warned that financial engineering could distract from fixing the core business, saying it “could end up being a distraction.” Reuters

Before the next session, traders will be watching for any filings or public steps that clarify TCIM’s position and agenda, which can range from private talks to board nominations and proxy fights.

Technical levels are also in focus after the spike, with $100 in play as a round-number marker. The stock’s latest day range was $96.54 to $103.03, Google Finance data showed.

On the macro calendar later Monday, investors will track U.S. data including advance international trade in goods and the National Association of Realtors’ pending home sales index, alongside the Dallas Fed’s manufacturing survey, according to the New York Fed’s calendar.

Target has not confirmed its next earnings publication date, but MarketBeat estimates the report around March 3, before the open, based on past schedules. That update is expected to sharpen focus on holiday-quarter margins and whether comparable sales stabilize.

Stock Market Today

  • Teradyne, Kulicke and Soffa, Impinj, Microchip, IPG Photonics Stocks Slide on U.S.-China Semiconductor Summit Outcome
    May 21, 2026, 2:58 AM EDT. Shares of Teradyne, Kulicke and Soffa, Impinj, Microchip Technology, and IPG Photonics dropped sharply following the U.S.-China summit, which ended without key breakthroughs on semiconductor exports. Expectations for U.S. approval of Nvidia's H200 chip shipments to China were unmet, disappointing investors. U.S. Trade Representative Jamieson Greer indicated semiconductors were not a negotiation focus, dampening near-term optimism. Despite the sell-off, IPG Photonics' stock, known for volatility, remains down significantly from its 52-week high but has gained 34.3% year-to-date. Market reactions highlight cautious sentiment amid geopolitical tensions, with analysts skeptical about swift comprehensive deals due to national security concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
HFCL jumps 10% on heavy volumes even as MarketsMojo keeps “Strong Sell” callNEW YORK, December 29, 2025, 00:11 ET
Previous Story

HFCL jumps 10% on heavy volumes even as MarketsMojo keeps “Strong Sell” callNEW YORK, December 29, 2025, 00:11 ET

Hims & Hers stock slides into year-end as investors weigh Ohio buildout and macro calendar
Next Story

Hims & Hers stock slides into year-end as investors weigh Ohio buildout and macro calendar

Go toTop